Share on StockTwits

Theravance (NASDAQ:THRX) posted its quarterly earnings results on Thursday. The company reported ($0.46) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.38) by $0.08, Stock Ratings reports. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $6.03 million.

On the ratings front, analysts at Zacks reiterated a “neutral” rating on shares of Theravance in a research note to investors on Tuesday, January 7th. They now have a $38.00 price target on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $35.94.

Shares of Theravance (NASDAQ:THRX) traded up 0.11% on Thursday, hitting $36.13. 1,413,871 shares of the company’s stock traded hands. Theravance has a one year low of $19.71 and a one year high of $42.96. The stock’s 50-day moving average is $36.60 and its 200-day moving average is $37.16. The company’s market cap is $3.994 billion. Theravance also was the target of a significant growth in short interest in January. As of January 15th, there was short interest totalling 13,087,030 shares, a growth of 12.8% from the December 31st total of 11,412,149 shares. Based on an average daily trading volume, of 889,702 shares, the days-to-cover ratio is presently 14.7 days. Approximately 17.0% of the shares of the stock are short sold.

Theravance, Inc (NASDAQ:THRX) is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.